Preoperative ultrasound-guided multilevel paravertebral blocks reduce the incidence of postmastectomy chronic pain: a double-blind, placebo-controlled randomized trial.

PURPOSE: Chronic postsurgical pain is a challenging problem after breast cancer surgery. This prospective, randomized, double-blinded, parallel-group, placebo-controlled trial was conducted to evaluate the influence of preoperative ultrasound-guided multilevel paravertebral blocks (PVBs) on chronic pain following mastectomy. PATIENTS AND METHODS: One hundred eighty-four women were randomized to receive ultrasound-guided multilevel (T1-T5) PVBs with 5 mL of ropivacaine 0.5% or normal saline per level. The primary end point was the incidence of chronic pain at 3 months following mastectomy assessed by the brief pain inventory (BPI), while the secondary end points were the acute postoperative pain, the number of patients requiring rescue analgesia, postoperative nausea and vomiting (PONV), side effects, and chronic pain at 6 months after surgery assessed by the BPI.
RESULTS: A total of 172 patients completed the study. Ultrasound-guided multilevel PVBs significantly decreased immediate postoperative pain for the first 12 hours (P<0.001). Additionally, fewer patients in the PVB group required rescue analgesia in the first 48 hours post-operatively compared to the control group (5/86 vs 28/86, OR =0.128, 95% CI: 0.047-0.351, P<0.001). No statistically significant difference was tested between the two groups (9.3% vs 17.4%, OR =0.419, 95% CI: 0.162-1.087, P=0.068) in the incidence of PONV. At 3 months, the incidence of chronic pain (BPI average pain score ≥3) was 34.5% and 51.2% (OR =0.511, 95% CI: 0.277-0.944, P=0.031) in the PVB and control groups, respectively, and at 6 months, the incidence was 22.1% and 37.2% (OR =0.479, 95% CI: 0.245-0.936, P=0.03), respectively. No complications occurred during the study.
CONCLUSION: This study indicated that perioperative ultrasound-guided multilevel PVBs with ropivacaine improved acute postoperative pain and decreased postmastectomy chronic pain at 3 and 6 months postoperatively.

Introduction

Breast cancer is the most common type of cancer and the leading cause of cancer-related death among women.1 Acute postoperative pain is frequently moderate or even severe following breast cancer surgery. There is cumulative evidence that postoperative pain is closely associated with subsequent persistent pain lasting months. The International Association for the Study of Pain has defined chronic postsurgical pain (CPSP) as a pain that develops after surgical intervention and persists at least 2 months.2 The prevalence of CPSP has been reported in 25%–60% of patients after breast cancer surgery.3–5 Chronic postoperative pain has a large negative impact on the quality of life due to psychological distress and disability.6 Therefore, it has become an important clinical issue.

Thoracic paravertebral block (PVB) is one of the multi-modal pain relief strategies, and the role of PVB in preventing chronic pain following breast cancer surgery has gained interest, but existing evidence is few and conflicting.7,8 In the literature, the technical aspect of PVB used varies considerably. The relatively high failure rates of landmark-guided PVB technique may contribute to methodological bias.9 The ultrasound-guided PVB technique was first described by Hara et al,10 which has been proved to improve regional and peripheral nerve block success rates. However, the effect of ultrasound-guided multilevel single-injection PVBs on CPSP after breast cancer surgery remains unclear.

We hypothesized that preoperative ultrasound-guided multilevel PVBs could provide effective analgesia during the perioperative period and may reduce postmastectomy chronic pain. Therefore, we designed this prospective randomized double-blind placebo-controlled trial to address the influence of ultrasound-guided multilevel PVBs on the incidence and intensity of CPSP after breast cancer surgery.

Patients and methods

Design and patients

This prospective, randomized, double-blind, placebo-controlled trial was conducted in line with the Declaration of Helsinki and the CONSORT statement. The study protocol was approved by the Clinical Research Ethics Committee of Fujian Provincial Hospital (No. K2014-11-008) and registered at http://www.chictr.org.cn (ID: ChiCTR-INR-16007874) on February 14, 2016. Written informed consent was obtained from each patient before recruitment. Female patients aged 18–60 years old with an American Society of Anesthesiologists physical status I or II, who were scheduled to undergo unilateral partial mastectomy with or without axillary lymph node dissection, were assessed for study eligibility. Exclusion criteria included the following: contraindications to PVB such as allergy to local anesthetics, infection, or coagulopathy; intake of analgesic within 24 hours before surgery; and unable to comply with the study protocol for any reason.

The randomization (1:1 ratio) was performed using a website random number generator (www.randomization.com). Assignments were concealed in sequentially numbered, opaque, sealed envelopes, and the envelopes were not opened until the day of the surgery. The consecutively enrolled patients were randomly assigned to either ropivacaine or saline PVB. All attending anesthesiologists, patients, and data collectors were unaware of treatment group assignment.

Anesthetic procedure

No premedication was given before anesthesia. Routine monitoring included electrocardiograph, pulse oximetry, capnography, noninvasive blood pressure, and temperature. Anesthesia was induced with sufentanil 0.5 µg/kg and pro-pofol 2.0 mg/kg. Laryngeal mask airway (LMA) intubation was facilitated with intravenous cisatracurium 0.15 mg/kg. After LMA intubation, the ventilation parameters were standardized (tidal volume 8–10 mL/kg, respiratory rate 12–15 bpm, a fraction of inspired oxygen 50%) to achieve 35–45 mmHg of PETCO2. Anesthesia was maintained with an end-tidal sevoflurane 1.5%–3% to achieve the hemodynamic changes within 20% of baseline and a bispectral index of 40–60. Neuromuscular block was reversed by the administration of neostigmine 0.02 mg/kg and atropine 0.01 mg/kg, if necessary.

All patients were transferred to the postanesthesia care unit for 2 hours. Routine postoperative analgesia was administered including intravenous flurbiprofen axetil 50 mg every 12 hours and sufentanil for patient-controlled intravenous analgesia (PCIA). The PCIA was programmed to deliver a bolus of sufentanil 2 µg on demand with a 10-minute lockout interval and a background infusion of sufentanil 2 µg/h.

Postoperative pain at rest was rated using a numeric rating scale (NRS) of 0 (no pain) to 10 (worst pain imaginable). If the NRS score was ≥4 or if the patient required, sufentanil 2 µg was administered as a rescue analgesic by the PCIA device. Tropisetron 5 mg plus dexamethasone 10 mg was administered for nausea and vomiting prophylaxis after LMA insertion.

Ultrasound-guided multilevel PVBs

All patients received the ultrasound-guided PVBs between the first and fifth thoracic vertebrae in the prone position prior to surgery. This procedure was performed according to the methods described by the literature.11,12 The thoracic paravertebral space was scanned by ultrasonography (Model Edge; FUJIFILM SonoSite, Inc., Bothell, WA, USA) with a 2–5 MHz curved array ultrasound probe. The ultrasound probe was positioned in the vertical plane ~2 cm lateral to the spinous process. A 21 G, 80 mm, Uniplex Nanoline needle (PAJUNK GmbH Medizintechnologie, Geisingen, Germany) was advanced in an in-plane orientation toward the desired paravertebral space. Then, the needle was introduced to puncture the superior costotransverse ligament. After the position of the needle tip was confirmed, a total volume of 25 mL of ropivacaine 0.5% or normal saline (5 mL per level) was administered at the T1–T5 levels.

Outcomes

The primary end point was to address whether the use of ultrasound-guided multilevel PVBs with ropivacaine reduced the incidence of postmastectomy chronic pain 3 months after surgery. Chronic pain was defined by a score of ≥3 on the single item (average pain) of the brief pain inventory (BPI).13,14 The BPI consists of three domains: 1) pain intensity (4 items), measured using an NRS of 0 (no pain) to 10 (worst pain imaginable); 2) pain’s interference with daily activities (7 items), measured using a scale of 0 (no interference) to 10 (complete interference); and 3) percentage of relief provided by pain treatments, measured using a scale of 0 (complete relief) to 10 (no relief). A composite score of BPI ranging from 0 (optimal) to 120 (worst possible) was also recorded according to Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials recommendations.15 A research nurse, who was blinded to treatment group, conducted a telephone interview with the patients at 3 and 6 months following mastectomy. Secondary end points were the acute postoperative pain, the number of patients requiring rescue analgesia, postoperative nausea and vomiting (PONV), side effects, and chronic pain at 6 months after surgery assessed by the BPI. Acute postoperative pain at rest was assessed using an NRS at 0.5, 1, 2, 4, 8, 12, 24, and 48 hours following breast cancer surgery.

Statistical analysis

The sample size calculation was based on the primary end point (the incidence of chronic pain at 3 months). The estimated prevalence of chronic pain in the literature is 40% at 3 months. In order to detect a 50% reduction of the incidence of chronic pain (from 40% to 20%), a sample size of 82 subjects per group would be required to achieve an alpha of 0.05 and obtain 90% power. Allowing for 10% of patients’ incomplete follow-up or dropout, a population of 184 patients was required in this study.

All continuous data were tested for normality of distribution via the Shapiro–Wilk test. Parametric variables were reported as mean (SD) and analyzed with the two-sample independent t-test, and nonparametric variables were reported as median (IQR) and analyzed with the Mann–Whitney U-test. For the evaluation of postoperative NRS scores, we used a repeated measures analysis with post hoc testing. Categorical variables were reported as number (percentage) and compared by the chi-squared or Fisher’s exact test when necessary. All reported P-values are two-tailed, and a P-value of <0.05 was considered statistically significant.

Results

We investigated 207 patients for eligibility to participate in this study from March 12, 2016 to February 16, 2018 at Fujian Provincial Hospital. A CONSORT flow diagram describing the progression of subjects through the study is presented in Figure 1. Of the 207 patients, 9 did not meet the inclusion criteria and 14 declined to participate, and the remaining 184 patients were enrolled in this study. Two patients in the PVB group and one patient in the control group were later excluded due to protocol breach. In addition, four patients in the PVB group and five patients in the control group could not be reached for follow-up. Finally, 172 patients completed the study and their data were analyzed. Demographic characteristics and type and duration of surgery were not statistically different between groups (Table 1).

Figure 1

CONSORT flow diagram describing the progression of subjects through the study.

Abbreviation: PVB, paravertebral block.

Table 1

Demographic data and clinical characteristics of the patients in the study

Variables	PVB group (n=86)	Control group (n=86)	P-value
Age (years)	46.5±6.7	44.8±7.2	0.498
Body weight (kg)	58.5±7.4	60.2±7.8	0.379
BMI (kg/m2)	23.9±4.4	24.3±5.1	0.713
ASA physical status (I/II)	31/55	37/49	0.349
Duration of surgery (minutes)	116±16	128±17	0.537
Type of surgery
Partial mastectomy with ALND	34 (39.5%)	39 (45.3%)	0.44
Partial mastectomy without ALND	52 (60.5%)	47 (54.7%)

Note: Values are reported as mean ± SD or number (percentage).

Abbreviations: ALND, axillary lymph node dissection; ASA, American Society of Anesthesiologists; BMI, body mass index; PVB, paravertebral block.

The acute postoperative pain scores during the first 48 hours following surgery at rest are shown in Figure 2. Briefly, the NRS scores were lower in the first 12 hours postoperatively in the PVB group compared to the control group (P<0.001). Additionally, at 24 and 48 hours postoperatively, there was no difference detected between the groups in the NRS scores. As shown in Table 2, ultrasound-guided multilevel PVBs with ropivacaine decreased the number of patients requiring rescue analgesia for the first 48 hours (5/86 vs 28/86, OR =0.128, 95% CI: 0.047–0.351, P<0.001). In addition, the incidence of PONV was 9.3% in the PVB and 17.4% in the control group, and no statistically significant difference was observed (OR =0.419, 95% CI: 0.162–1.087, P=0.068). No episodes of PVB-related complications (such as local anesthetic toxicity, pneumothorax, epidural or sub-arachnoid injection) were observed.

Figure 2

The NRS scores at rest during the first 48 postoperative hours. The NRS showed lower scores at rest in the first 12 hours after surgery in the PVB group than the control group (*P<0.001).

Abbreviations: NRS, numeric rating scale; PVB, paravertebral block.

Table 2

Outcome measurements during the period of the study

Variables	PVB group (n=86)	Control group (n=86)	P-value
Incidence of chronic pain
At 3 months	30 (34.9%)	44 (51.2%)	0.031
At 6 months	19 (22.1%)	32 (37.2%)	0.03
BPI total score (0–120)
At 3 months	7 (14)	18 (17)	<0.001
At 6 months	5 (9)	8 (19)	<0.001
Number of patients requiring analgesics	5 (5.8%)	28 (32.6%)	<0.001
PONV	7 (9.3%)	15 (17.4%)	0.068

Note: Values are reported as median (IQR) or number (percentage).

Abbreviations: BPI, brief pain inventory; PONV, postoperative nausea and vomiting; PVB, paravertebral block.

The BPI average pain scores evaluated 3 and 6 months after surgery are presented in Figure 3. Correspondingly, the total of BPI scores at 3 and 6 months postoperatively in the PVB group was lower compared with the control group (both P<0.001, Table 2). At 3 months, the incidence of chronic pain (BPI average pain score ≥3) was 34.5% and 51.2% in the PVB and control groups, respectively (Table 2), and patients in the PVB group had lower odds of developing chronic pain compared to the control group (OR =0.511, 95% CI: 0.277–0.944, P=0.031). Similarly, at 6 months, the incidence of chronic pain was 22.1% and 37.2% in the PVB and control groups, respectively (Table 2), and patients in the PVB group had lower odds of developing chronic pain than the control group (OR =0.479, 95% CI: 0.245–0.936, P=0.03).

Figure 3

Box plots of BPI average pain score in patients receiving PVBs either with ropivacaine 0.5% or with normal saline. The median BPI pain score in the PVB group was lower compared with the control group at 3 and 6 months postoperatively (P=0.022 and P=0.009, respectively).

Abbreviations: BPI, brief pain inventory; PVB, paravertebral block.

Discussion

This prospective, randomized, double-blind, parallel-arm, placebo-controlled follow-up study suggested that preoperative ultrasound-guided single-injection multilevel PVBs significantly reduce acute postoperative pain and chronic pain after breast cancer surgery. Our results of the NRS of acute postoperative pain and the number of patients requiring rescue analgesia indicated that perioperative ultrasound-guided multilevel PVB can be used as a potent adjuvant for the multimodal management of pain following mastectomy. Although the effective duration of single-injection PVBs is <24 hours, the effect of PVBs against chronic pain can last for 3 and 6 months following mastectomy. Our findings have broad clinical implications considering that tens of thousands of women undergoing breast cancer surgery have a relatively high risk of developing chronic pain.

In this study, the score of intensity of acute postoperative pain at rest was mostly <3 on the NRS, and a statistically significant difference between the two groups was observed at least in the first 12 hours. These findings corroborate the existing literature and demonstrate PVBs improve postoperative pain control in patients undergoing mastectomy.16,17 In addition to alleviating acute postoperative pain, PVBs decrease the risk for the development of chronic pain. The BPI average pain scores and the total of BPI scores were evaluated at both 3- and 6-month follow-up as outcomes in this study. In general, 3 months is the earliest period for pain to be classified as chronic,18 but 6 months is more likely to allow enough time for recovery from swelling and acute postsurgical inflammatory processes.19 In this study, the overall incidence of chronic pain was 43% and 29.7% at 3 and 6 months, respectively, which is in line with the previous reports (25%–60%).3–5 This wide range of prevalence of chronic pain in the literature is probably due to differences in the definitions of chronic pain considered, the methods used to evaluate pain intensity, time taken for CPSP assessment, and the type of surgery performed. The pathogenesis of CPSP is still not completely clear, but evidence continues to accumulate concerning the role of sensitization in chronic pain after surgery.20 The methods suggested for preventing CPSP include reduction of reversible peripheral and central neuronal sensitization, reduction of inflammatory responses, as well as use of minimally invasive operative procedures.21 Therefore, regional or peripheral nerve blockade is widely used to diagnose and treat chronic postoperative pain. Historically, in most cases, chronic pain after breast surgery has been attributed to nerve damage, which results in spinal sensitization, expansion of sensory receptive fields, and alterations in the processing of innocuous stimuli. In this study, hyperalgesia did not develop when local anesthetic injection was administered before surgery. This mechanism may have contributed to less postoperative NRS pain scores in the PVB group, in which multilevel PVBs were inserted before incision.

PVBs have minimal effects on cardiovascular variables. No episodes of clinically significant hypotension or bradycardia were identified in this study, which may be attributed to the less sympathetic blockade and unilateral segmental nature of the block. In addition, although this study was not powered to detect the difference in the incidence of PONV, patients who received PVBs showed a beneficial trend, which may partly reflect the PVBs’ opioid-sparing effect. Moreover, no block-related complications (such as local anesthetic toxicity, pneumothorax, epidural or subarachnoid injection) occurred during the study. Actually, the incidence of complications was very low, and ultrasound further provided significant improvements in regional anesthesia.

Several limitations of this study need to be addressed when interpreting the results. First, our study did not examine possible psychological factors influencing chronic pain. However, a previous report suggested that preoperative emotional variables (such as anxiety or depression) did not independently contribute to the risk of developing CPSP after surgery.22 Second, we conducted this study in a single hospital and patients were treated based on consistent guidelines. Thus, this may potentially limit the external validity of our findings. Third, our Research Ethics Committee suggested us that acute postoperative pain cannot be considered as a primary outcome and evaluating the pain intensity at movement may be unfavorable for the patients. Therefore, we only examined the acute postoperative pain at rest which caused a potential bias in this study. In addition, we did not confirm whether the PVBs were administered successfully by testing sensory blockade due to the blinded nature of the trial. However, administration of all the PVBs was performed using real-time ultrasound guidance by a single experienced anesthesiologist. Thus, we believe that the majority of the PVBs were successfully administered.

Conclusion

In summary, our findings suggest that perioperative ultrasound-guided single-injection multilevel PVBs with ropivacaine may be protective against CPSP at 3 and 6 months following breast cancer surgery.

Data sharing statement

The individual participant data underlying published results can be accessed with approval from the principal investigator after 6 months of publication of main results. The study protocol, statistical analysis plan, and clinical study report will also be available.